医薬経済は医療・医薬を取り巻く環境の“いま”にフォーカス!

MENU

RISFAX November 16, 2018

日本語

”Major” pending issues include “timing” of start and price adjustments
Full rollout of cost-effectiveness assessment: Products similarly listed in FY2019 may include those outside and inside the scope

Japan’s first solid tumor indication for “KEYTRUDA”
Second Committee on Drugs on November 29 to deliberate “HEMLIBRA” for patients without factor VIII inhibitors and a new hepatitis C treatment, too